ProQR Therapeutics N.V.
PRQR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $19 | $7 | $4 | $1 |
| % Growth | 190.2% | 81.2% | 169.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $19 | $7 | $4 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $36 | $25 | $51 | $42 |
| G&A Expenses | $14 | $16 | $19 | $17 |
| SG&A Expenses | $14 | $16 | $19 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | -$3 | -$1 | -$1 |
| Operating Expenses | $49 | $38 | $69 | $59 |
| Operating Income | -$30 | -$32 | -$65 | -$57 |
| % Margin | -161.2% | -489.1% | -1,813% | -4,285.4% |
| Other Income/Exp. Net | $3 | $4 | $1 | -$3 |
| Pre-Tax Income | -$28 | -$28 | -$64 | -$61 |
| Tax Expense | -$0 | -$0 | $0 | $0 |
| Net Income | -$28 | -$28 | -$64 | -$61 |
| % Margin | -146.9% | -431.7% | -1,792.5% | -4,549.8% |
| EPS | -0.34 | -0.35 | -0.91 | -0.96 |
| % Growth | 2.9% | 61.5% | 5.2% | – |
| EPS Diluted | -0.34 | -0.35 | -0.91 | -0.96 |
| Weighted Avg Shares Out | 82 | 81 | 72 | 64 |
| Weighted Avg Shares Out Dil | 82 | 81 | 72 | 64 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $0 | $0 |
| Interest Expense | $1 | $1 | $5 | $3 |
| Depreciation & Amortization | $3 | $3 | $3 | $2 |
| EBITDA | -$24 | -$24 | -$56 | -$55 |
| % Margin | -127.6% | -369.9% | -1,571% | -4,116% |